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Abstract A single copy of a glucocorticoid-responsive el ment 
(GRE) is sufficient in mediating the combinatorial response of a 
promoter to both glucocorticoids and insulin in HepG2 cells. This 
requires the presence of active glucocorticoid receptor (GR) since 
the response is significantly inhibited by the anti-ghicocorticoid 
RU30406. The N'- and C'-terminal parts of the GR protein are 
not involved in mediating the response. Insulin had no effect on 
GR binding to GRE but it affected both the level and the 
phosphorylation state of nuclear-bound GR. Thus, insulin alters 
the GR transactivation potency while, concomitantly, modifies 
the molecule at the posttranslational level. 
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1. Introduction 
Glucocorticoid hormones exert their action by binding to 
an intracellular glucocorticoid receptor (GR) which undergoes 
conformational changes, rapidly translocates to the nucleus 
and by binding to target DNA sequences (termed GREs), 
modulates gene transcription (for review see [1]). Cloning of 
the cDNA coding for the GR revealed protein domains re- 
sponsible for its function including steroid binding, DNA 
binding, as well as transcriptional transactivation [2,3]. These 
domains are also thought o function by interacting directly 
or indirectly with basal transcription machinery [4]. Some re- 
ports suggested that signalling cross-talk confers interaction 
of GR with other signal-dependent transcription factors re- 
suiting in positive or negative synergism on gene transcription 
[5]. Synergistic transactivation has been observed between GR 
and other factors. That could occur either by contacting of 
the different activators in separate targets [6] or by interaction 
of a GR complex with the other factors via a distinct domain 
[7]. 
Steroid hormone receptors have been shown to exist as 
phosphoproteins i  intact cells but the exact role of phosphor- 
ylation in their action has not been defined as yet. All steroid 
receptors exhibit ligand-dependent phosphorylation mainly on 
Ser/Thr residues, which is complicated and proceeds at multi- 
ple steps. Rabbit uterine progesterone r ceptor undergoes two 
phosphorylation reactions, a cytosolic and a nuclear which is 
hormone-regulated [8].Mouse uterine oestrogen receptor has 
also been shown to undergo nuclear phosphorylation in vivo 
[91. 
Glucocorticoid receptor (GR) is phosphorylated in vitro in 
*Corresponding author. Fax: (30) (1) 7251827. 
**Deceased. 
rat liver cytosol by cAMP-dependent protein kinase and in 
vivo in the liver of adrenalectomized rat [I0]. GR is also 
phosphorylated in intact mouse fibroblasts (L cells) [11]. In 
rat liver cytosol, GR appeared as a major phosphoprotein of 
Mr 92,000 Da, while in L cells had an apparent Mr of 90,000 
Da. Using protease digestion and chemical cleavage reagents 
it was demonstrated that GR is phosphorylated mainly in xl : 
a potent transactivation domain lying in the NH2-terminal 
region of the molecule, on serine and threonine residues 
[12]. The DNA-binding domain of GR is also phosphorylated 
but phosphorylation f the hormone-binding domain has not 
been reported [13-15]. Modulation of GR function by the 
cAMP-dependent protein kinase (PKA) was demonstrated in 
F9 embryonal carcinoma cells. PKA enhanced the hormone- 
dependent transactivation f GR in these cells at least partly 
by increasing the DNA-binding activity of the receptor while 
its affinity for the steroid was unaffected [16]. 
In a previous report [17] we demonstrated that insulin sig- 
nalling increases the glucocorticoid inducibility on the 
MMTV-LTR promoter by 2-fold. We presented evidence 
that the synergistic effect was GR-dependent and sequence 
specific and that it affected the initiation rate of RNA syn- 
thesis. Here we analyze the insulin effect on the functional 
properties of the GR as well as on its phosphorylation pat- 
tern. Our results clearly demonstrate hat the increase of the 
GR transactivation by the combinatorial ction of both hor- 
mones complies with modulation of GR phosphorylation. 
2. Materials and methods 
2.1. Plasmids 
The constructs GRE-37TK and 2GRE-37TK which carry one and 
two copies respectively of the distal GRE located on the promoter of 
the rat tyrosine aminotransferase gene (TAT) were kindly provided by 
Dr. W. Schmidt [6]. The GRE in these constructs i placed in front of 
a minimal thymidine kinase (tk) promoter [18] followed by the coding 
region of the chloramphenicol acetyl transferase gene (CAT). The 
construct -37TK carries only the minimal thymidine kinase (tk) pro- 
moter followed by the coding region of the CAT gene [6]. The con- 
struct MMTVlx carries one copy of the distal GRE located on the 
mouse mammary tumour virus (MMTV) promoter and was kindly 
provided by Dr. M. Beato. The construct pRSVGR has the cDNA of 
rat GR in front of the promoter of Rous sarcoma virus (RSV) [19]. A 
deletion series of pRShGRa which carries the cDNA of human GR 
was also used. The deletion mutants are A9-385, A428-490 and 1559. 
The last construct has a point mutation in the cDNA region that 
encodes for the C'-terminal part of GR [20]. Finally we used the 
plasmid pRSVGal with the ~-galactosidase gene driven by the RSV 
promoter. 
2.2. Cellular transfection assays 
Human hepatoma HepG2 cells were cultured in phenol red-free 
minimal essential medium (MEM) containing 10% (v/v) fetal calf ser- 
um (FCS), 100 U/ml penicillin, 100 mg/ml streptomycin a d 2 mM 
glutamine. One day prior to transfection cells were plated in petri 
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Fig. 1. Effect of insulin and dexamethasone on CAT activity after 
transfection of HepG2 cells with GRE-37TK and 2GRE-37TK. The 
cells were transiently co-transfected with 10 I.tg of the reporter plas- 
mid, 5 ~tg of pRSVGR and 3 btg of pRSVGal after 24 h incubation 
in MEM supplemented with 0.5% (v/v) inactivated serum and 1.5% 
(w/v) BSA. 24 h later the cells were treated with dexamethasone 
(Dex) insulin (Ins) and the synthetic antiglucocorticoid RU30406 
(RU). CAT activity was determined in cell extracts corresponding 
to 1.5 units of i3-galactosidase activity and it was expressed in units. 
One unit is the CAT activity in the absence of hormones. Values 
were adjusted to protein concentration measured by Bradford. The 
reporter plasmids were -37TK and GRE-37TK in (A) and 2GRE- 
37TK in (B). The reported values are the mean_+S.D, of 3 or more 
individual experiments. 
dishes at a density of 1.5 x 106 cells/dish (,~ 50% confluence) in med- 
ium with 0.5% (v/v) heat-inactivated and charcoal-stripped FCS sup- 
plemented with 1.5% (w/v) BSA. Transfection was carried out by the 
calcium phosphate co-precipitation technique [21] with minor modifi- 
cations. 10 i.tg of reporter plasmid DNA were co-transfected with 5 Ixg 
of pRSVGR or deletion mutants per dish. Transfection efficiency was 
controlled by co-transfection of the internal reference plasmid 
pRSVGal (3/.tg). 4~6 h later the precipitate was removed and the cells 
were shocked for 30 s with medium containing 15% (v/v) glycerol. The 
cells were then washed with phosphate-buffered saline and cultured in 
medium with 0.5% (v/v) inactivated FCS and 1.5% (w/v) BSA. After a 
20-h recovery period, hormones were added and allowed to act for 
another 22 h. Dexamethasone and insulin were added to final con- 
centrations of 1 I.tM and 7 nM respectively while the synthetic anti- 
glucocorticoid RU30406 was added at a concentration f 10 ~tM. The 
cells were harvested by scraping and cellular extracts, prepared by 
three cycles of freeze-thawing in 0.25 M Tris-HCl (pH 7.8), were 
heat-treated for 10 min in 60°C in order to inactivate the deacetylase 
activity [22]. Protein concentration was determined by the method of 
Bradford and 13-galactosidase activity in the extracts, produced by 
pRSVGal, was used to compensate variations in transfection efficien- 
cies. Mouse fibroblasts (Ltk-) were transfected asdescribed above in 
MEM with 10% (v/v) inactivated FCS. The cells were co-transfected 
with 10 ~tg of 2GRE-37TK reporter plasmid and 5 lag of pRSVGal as 
a reference plasmid. 
2.3. Electrophoretic mobility shift assay 
HepG2 cells were transiently transfected with 5 lag of pRSVGR and 
3 Ixg of pRSVGal and treated with hormones as described above. 
Cells were washed in phosphate-buffered saline and disrupted in buf- 
fer A (10 mM HEPES pH 7.9, 1.5 mM MgCI~, 10 mM KCI, 0.5 mM 
DTT) by a 5-6 times passage through a 1-ml syringe with a 26-gauge 
needle. Nuclei were isolated and subsequently resuspended in buffer I
(10 mM Tris-HC1 pH 8.0, 0.32 M sucrose, 3 mM CaC12, 2 mM 
magnesium acetate, 0.1 mM EDTA, 0.1% (v/v) Triton X-100, 1 mM 
DTT and 2× 10 -4 M PMSF), mixed with two volumes of buffer II (10 
mM Tris-HC1 pH 8.0, 2 M sucrose, 5 mM magnesium acetate, 0.1 
mM EDTA, I mM DTT and 2X 10-4M PMSF), layered on buffer Ili 
(10 mM Tris-HCl pH 8.0, 1.5 M sucrose, 0.1 mM EDTA, 1 mM DTT 
and 2 x 10 -4 M PMSF) and pelleted by centrifugation at2000 x g for 
30 rain at 4°C. The pellet was washed two times with storage buffer 
(50 mM Tris-HC1 pH 8.0, 25% (v/v) glycerol, 5 mM magnesium acet- 
ate, 0.1 mM EDTA, 5 mM DTT and 2×10 -4 M PMSF) and nuclei 
were extracted in buffer C (20 mM HEPES pH 7.9, 500 mM KCI, 
1.5 mM MgC12, 25% (v/v) glycerol, 0.2 mM EDTA, 200 I.tg/ml BSA, 
0.5 mM DTT and protease inhibitors: 1 mM leupeptin, 0.2 mM 
PMSF, 5 ~tg/ml aprotinin, 5 pg/ml pepstatin and 5 lxg/ml antipain) 
in 4°C for 1 h, The DNA-binding activity of GR in nuclear extracts 
was analyzed by gel mobility shift assay using as specific DNA a 32- 
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Fig. 2. Effect of GR deletion mutants on the inducibility of dexa- 
methasone and insulin. HepG2 cells were transiently co-transfected 
with 10 /.tg of the reporter plasmid 2GRE-37TK, 3 /.tg of pRSVGal 
and 5 ~tg of A9-385 or 5 Ixg of A428-490 or 5 ~tg of 1559 after 24 h 
incubation in MEM supplemented with 0.5% (v/v) inactivated serum 
and 1.5% (w/v) BSA. 24 h later the cells were treated with dexa- 
methasone (Dex) and insulin (Ins). CAT activity was determined in
cell extracts corresponding to 1.5 units of I~-galactosidase activity 
and it was expressed in units. One unit is the CAT activity in the 
absence of hormones, mediated by the A428-490 deletion mutant. 
Values were adjusted to protein concentration measured by Brad- 
ford. The reported values are the mean + S.D. of 3 or more indivi- 
dual experiments. 
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Fig. 3. Effect of insulin on the DNA binding of the GR. HepG2 
cells were transiently co-transfected with 10 lag of the reporter plas- 
mid 2GRE-37TK, 5 lag of pRSVGR and 3 lag of pRSVGal after 24 
h incubation in MEM supplemented with 0.5% (v/v) inactivated ser- 
um and 1.5% (w/v) BSA. 24 h later the cells were treated with 1 I.tM 
dexamethasone (lanes 1-3), 7 nM insulin (lane 5) or both (lanes 6- 
8) and nuclei were isolated and salt extracted. The DNA binding ac- 
tivity of GR in 5 lag of nuclear extract was analyzed by gel mobility 
shift assay on a 4% non-denaturing polyacrylamide gel using a 3'- 
end labelled GRE as specific DNA. Competition experiments were 
carried out with a 500-fold molar excess of unlabelled GRE (sc, spe- 
cific competitor; lanes 2, 7) or  a 500-fold molar excess of an unre- 
lated unlabelled DNA fragment (nsc; non-specific ompetitor; lanes 
3, 8). The gel was dried and autoradiographed. 
base pair double-stranded synthetic oligonucleotide corresponding to
the most distal (-189 to -162) GRE located on the MMTV promoter 
(kindly provided by Dr. M. Beato). The GRE was 3'-end labelled 
with [t~-a2P]deoxy-CTP by Klenow polymerase. 5 lag of protein 
from each nuclear extract was incubated in reaction mixture (20 
mM Tris pH 8.0, 1.5 mM MgC12, 0.1 mM, 3 mg/ml BSA, 100 ng/ 
ml poly(dI-dC) and protease inhibitors: 1 mM leupeptin, 0.2 mM 
PMSF, 5 gg/ml aprotinin, 5 gg/ml pepstatin and 5 lag/ml antipain) 
for 10 min on ice. After that 20 fmol of labelled GRE were added and 
the incubation continued for 20 rain at 22°C. A 500-fold concentra- 
tion of unlabelled GRE was used as a specific competitor while a 500- 
fold concentration of an unrelated DNA fragment was used as a non- 
specific competitor. Samples were subjected to electrophoresis on a 
non-denaturing 4% acrylamide gel pre-run for 30 min at 10 mA in 
Tris-borate buffer (45 mM Tris-borate, 1mM EDTA pH 8.0). The gel 
run at 1.5 mA/cm of gel in 4°C and was subsequently dried and 
autoradiographed. The bands corresponding to GR-GRE complexes 
were excised and measured for radioactivity in a liquid scintillation 
counter. Values were adjusted to ~-galactosidase activity measured in 
cell extracts. 
2.4. In vivo labelling of GR 
HepG2 cells were transiently transfected with 5 lag of pRSVGR as 
described above. 24 h after transfection the medium was changed to 
phosphate-free and serum-free MEM (without phenol red) for 1 h. 
The cells were then metabolically-labelled with 0.2 mCi/ml 
[32p]orthophosphate (Amersham) for 2 h. The cells were pooled and 
separated into equal samples. Hormones were added for 10 and 20 
min and the incubations were quickly stopped by freezing the cells in 
liquid nitrogen. The cells were washed with phosphate-free medium 
supplemented with 10 mM NaF and collected in cold hypotonic buffer 
A (10 mM HEPES pH 7.9, 1.5 mM MgC12, 10 mM KCI, 0.5 mM 
DTT, 10 mM NaF and protease inhibitors: 1 mM leupeptin, 0.4 mM 
PMSF, 10 lag/ml aprotinin, 10 ~tg/ml pepstatin and 10 ~tg/ml antipain). 
After 10 min in 4°C the resuspended cells were disrupted and nuclei 
were isolated and purified as described above. Nuclei were extracted 
in buffer C (20 mM HEPES pH 7.9, 500 mM KCI, 1.5 mM MgCI2, 
0.2 mM EDTA, 0.5 mM DTT, 10 mM NaF and protease inhibitors: 
1 mM leupeptin, 0.4 mM PMSF, 10 I.tg/ml aprotinin, 10 I.tg/ml pep- 
statin and 10 Ixg/ml antipain) as described above. Insoluble material 
was pelleted with a centrifugation for 10 min in a microfuge and 
discarded. After adjusting the KC1 molarity to 140 mM, the extracts 
were precleared by a 1 h incubation with anti-mouse IgG-precoated 
protein A at 4°C. The protein concentration i the cleared nuclear 
extracts was determined according to Bradford and aliquots of equal 
protein amount were incubated overnight with 1 lag of a specific 
monoclonal anti-GR antibody (MGR3H6) [23] at 4°C. A nuclear 
extract from cells treated with dexamethasone for 10 min was incu- 
bated with antigen-blocked MGR3H6. The immunocomplexes were 
coupled to protein A-Sepharose which was precoated with anti-mouse 
lgG, by rotating them for 2 h at 4°C. Immunoprecipitates were 
washed successively with buffer C (with 140 mM KCI) and eluted in 
Laemmli sample buffer. After boiling for 5 min, the samples were 
centrifuged in a microfuge and the supernatants were subjected to 
electrophoresis on a 8% polyacrylamide gel. 14C-Labelled molecular 
weight standards were: myosin (Mr 200,000), ~-galactosidase (Mr 
116,000), phosphorylase b (Mr 94,000), bovine serum albumin 
(BSA) (Mr 67,000), ovalbumin (Mr 43,000). 
2.5. Immunoblotting 
Electrophoretic gels were transferred to nitrocellulose filters for 4 h 
at 300 mA. Non-specific antibody binding to the nitrocellulose was 
prevented by incubating the filter for 1 h at 37°C with block solution 
(3% (w/v) BSA, 10 mM Tris pH 7.5, 150 mM NaC1, 0.1 mM PMSF). 
The blot was incubated with the MGR3H6 monoclonal antibody at 
dilution 1:1000 (v/v) in binding buffer (0.125% (v/v) BSA, 10 mM Tris 
pH 7.5, 150 mM NaC1, 0.1 mM PMSF, 1% (v/v) Tween 20, 0.04% 
(v/v) NAN3) overnight at 4°C. Nitrocellulose was then washed with 10 
mM Tris pH 7.5, 150 mM NaC1, 0.05% (v/v) Tween 20 and 0.05% 
(v/v) NP-40, incubated for 2 h at room temperature with peroxidase- 
conjugated rabbit anti-mouse IgG at a 1:500 (v/v) dilution and then 
visualized by incubation with substrate buffer containing 0.18 mg/ml 
4-chloro-l-naphthol in 10 mM Tris pH 7.5, 150 mM NaCI, 6% (v/v) 
methanol and 0.02% (v/v) H202. The filter was then air-dried and 
autoradiographed using Fuji X-ray film. Densitometric scanning of 
the immunoblots was performed with a Molecular Dynamics personal 
densitometer. 
3. Results 
3. I. The combinatorial action of glucocorticoid and insulin 
signalling exerts synergistic effects on the activity of a 
single GRE 
In our previous report we demonstrated that the expression 
of a glucocorticoid-inducible reporter gene (pMMTV-5A)  was 
potentiated in the presence of both hormones [17]. In this gene 
the tk promoter was activated by a region of the MMTV-LTR 
( -362  to -70)  which contained four GREs  as well as targets 
for other transcription factors. In this study we are interested 
in determining the specific target of insulin by which the glu- 
cocorticoid induction was enhanced. We started by testing 
insulin targeting to the transcriptional complex GR-GRE 
using as reporter genes the GRE-37TK and 2GRE-37TK con- 
taining one and two copies respectively of the distal GRE of 
the rat tyrosine aminotransferase (TAT) promoter in front of 
a minimal tk promoter  [18] and the coding region of the CAT 
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Fig. 4. Hormone-dependent processing and phosphorylation f nuclear-bound GR. HepG2 cells were incubated for 24 h in MEM supplemented 
with 0.5% (v/v) FCS inactivated and 1.5% (w/v) BSA. The cells were transiently transfected with 5 p.g of pRSVGR and 24 h later they were 
metabolically abelled with 0.2 mCi/ml [32P]Orthophosphate for 4 h in phosphate- and serum-free MEM. After labelling they were treated with 
1 ktM dexamethasone and 7 nM of insulin for different periods of time. Nuclei were isolated and salt extracted. Receptors from 10 ~g of nucle- 
ar extract were immunoprecipitated with a specific monoclonal anti-GR antibody (MGR3H6) and subjected to SDS-PAGE. (A -- top). The 
proteins in the gel were transferred to nitrocellulose and the sheet was blotted with MGR3H6. Lane 1 = no hormonal treatment; lanes 
2,3,4 -- treatment with 7 nM of insulin, 1 p.M of dexamethasone and both 7 nM of insulin and 1 p.M dexamethasone, r spectively for 10 min; 
lanes 5,6,7 = the same hormonal treatment as in lanes 2,3,4 for 20 min; lane 8 = immunoprecipitation of nuclear eceptor with antigen-blocked 
MGR3H6. (A -- bottom) Densitometric scanning was done on immunoblots and protein levels of receptors, at different imes of hormonal 
treatment, were expressed as arbitrary densitometric integration units. The reported values are the mean + S.D. of 3 individual experiments. 
(B -- top). The nitrocellulose filter was dried and exposed to X-ray film to obtain the autoradiogram. Lane 1 = no hormonal treatment; lanes 
2,3,4 = treatment with 7 nM of insulin, 1 p.M of dexamethasone and both 7 nM of insulin and 1 ~tM dexamethasone, r spectively for 10 min; 
lanes 5,6,7 = the same hormonal treatment as in lanes 2,3,4 for 20 min; lane 8 = immunoprecipitation of nuclear eceptor with antigen-blocked 
MGR3H6. (B -- bottom) Immunoreactive bands corresponding to GR were excised from the nitrocellulose sheet and counted for radioactivity 
in a liquid scintillation counter. Values were expressed as 32P-incorporation per arbitrary integration unit. The reported values are the 
mean + S.D. of 3 individual experiments. 
gene. The reporter genes were cotransfected into HepG2 cells 
with pRSVGR, a plasmid which carries the cDNA of the rat 
glucocorticoid receptor, because these cells have extremely low 
levels of GR ([24] and data not shown). Indeed, the reporter 
plasmid pMMTV-5A, used for testing the response of HepG2 
cells to glucocorticoids, was not activated by dexamethasone 
(data not shown). As expected, exogenous receptor-mediated 
activation of GRE-37TK and 2GRE-37TK by hormone was 
,~ 3- and ,~ 5-fold, respectively (Fig. 1A and B). In the pres- 
ence of insulin, induction was enhanced by ,~ 3- and ,-,2.5- 
fold, respectively, while insulin alone had a very little effect on 
the basal CAT activity in either case. Moreover, the synergis- 
tic effect of dexamethasone and insulin was significantly in- 
hibited by a 10-fold excess of the anti-glucocorticoid 
RU30406, demonstrating that this effect requires the presence 
of active GR (Fig. 1B). The response to insulin observed with 
transfected GR is identical to the response of endogenous 
GR, since the synergistic effect was also detected in mouse 
fibroblasts (Ltk-)  or in HTC cells, where the relative abun- 
dance of the GR is high (data not shown). As expected, plas- 
mid GRE-37TK produced a weaker induction than the 
2GRE-37TK confirming that duplication of the GRE en- 
hances its hormone inducibility [6]. The expression of plasmid 
-37TK which carries the minimal tk promoter but lacks GREs 
was not affected by either dexamethasone or insulin alone or 
by the combination of  both hormones (Fig. 1A). These results 
show that the response of glucocorticoid inducible promoters 
to both dexamethasone and insulin is mediated by the GRE 
itself, a fact which requires an active GR. 
3.2. Structural requirements of GR-mediated transcriptional 
potentiation by insulin 
Since only active GR can mediate the complex effect of 
both hormones, we used deletion mutants of GR in order to 
characterize the importance of its functional domains on the 
phenomenon. We tested the effect of hormones on HepG2 
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cells transiently cotransfected with reporter plasmid 2GRE- 
37TK and GR deletion mutants. As Fig. 2 shows, mutant 
A9-385, which lacks the xl transactivation domain [25], re- 
suited in a ,~ 2.6-fold enhancement by insulin, of dexametha- 
sone-induced CAT activity, as observed with the wild-type 
GR (Fig. 1). Mutant A428-490, which lacks the DNA-binding 
domain and glucocorticoid-induced transactivation, was not 
capable of transactivation i the presence of either dexa- 
methasone alone or both dexamethasone and insulin. Mutant 
1559, a constitutive transactivator, which lacks part of the 
steroid binding domain, supported the insulin effect since in- 
sulin enhanced constitutive CAT activity by ~ 2.1-fold (Fig. 
2). These results suggest hat the N'-  and the C'-terminal 
regions of the GR molecule are not critical for mediating 
the effect of insulin. 
3.3. Insulin does not affect the DNA binding of the GR 
In an effort to find if there exists an insulin-dependent, GR- 
targeted factor which stabilizes GR-GRE interaction, we tran- 
siently transfected HepG2 cells with pRSVGR plasmid and 
treated them with hormones as described in section 2. Nuclei 
were isolated, salt extracted, extracts were incubated with a 
synthetic, 3'-end-labelled GRE and DNA-protein complexes 
were analyzed in non-denaturing polyacrylamide g l (Fig. 3). 
As we can see in Fig. 3 nuclear GR from dexamethasone- 
treated cells was capable of binding to its cognate response 
element (GRE) (lane 1) while no retarded band was observed 
in the absence of hormones (lane 4). Similarly, no GR-GRE 
complex was observed with nuclear extracts from insulin- 
treated cells (lane 5). In the presence of both hormones, 
neither GR binding to the GRE was enhanced (lane 6) nor 
any slower migrating bands appeared in the gel. GR binding 
to labeled GRE was completely abolished in the presence of 
500-fold molar excess of specific, unlabelled competitor 
(GRE) in the reaction mixture (lanes 2 and 7), while a 500- 
fold molar excess of an unrelated DNA fragment could not 
prevent formation of the complex (lanes 3 and 8). Thus, in- 
sulin does not seem to affect the specific GR-GRE complex 
that is formed in the presence of dexamethasone. The data 
exclude the possibility that insulin signalling stimulates a fac- 
tor to interact directly with the GR or the GR-GRE complex. 
3.4. Insulin alters nuclear-bound GR levels and modulates 
nuclear receptor phosphorylation 
That changes in GR functional properties could not ac- 
count for the increase in GR transactivation by insulin 
prompted us to search for insulin-induced postranslational 
modifications of GR. It is well known that GR is a phospho- 
protein [26-28] and that insulin induces phosphorylation of
various cellular substrates, mediated by its receptor, a protein 
tyrosine kinase [29]. We decided to examine the effect of in- 
sulin in the phosphorylation state of nuclear-bound GR. A 
detailed time course of changes in receptor phosphorylation 
and nuclear-receptor levels was conducted following hormone 
addition. Nuclear-bound receptor levels from HepG2 cells 
transiently transfected with pRSVGR and metabolically la- 
belled with [32p]orthophosphate w re detected by immuno- 
blotting with a highly specific anti-GR monoelonal antibody 
(MGR3H6) that does not recognize other steroid receptors 
[23]. Changes in nuclear receptor levels (Fig. 4A) were com- 
pared to phosphorylation changes (Fig. 4B) at different imes 
of hormone treatment. In untreated cells, the level of GR 
phosphorylation was low (Fig. 4B, lane 1) but invariably in- 
creased following cell treatment with dexamethasone for 10 
min (Fig. 4B, lane 3), while it decreased after 20 min of hor- 
mone action (Fig. 4B, lane 6 and bottom). Nuclear-bound GR 
levels also increased in the presence of dexamethasone to
reach a maximum at 20 min (Fig. 4A, lane 6 and bottom). 
That steroid-induced levels of the nuclear-bound receptor 
were maximal at 20 min was confirmed by [3H]triamcinolone 
acetonide (TA) binding experiments (data not shown). Anti- 
gen-blocked MGR3H6 could not immunoprecipitate GR 
(Fig. 4A, lane 8; and Fig. 4B, lane 8). Insulin treatment re- 
producibly resulted in a 4 _+ 0.37-fold (n = 3) increase of the 
steroid-induced phosphorylation of GR at 10 min (Fig. 4B, 
lane 4 and bottom) which was not due to elevated nuclear- 
bound receptor levels. In fact, nuclear-bound GR levels were 
much lower at 10 min in the presence of both hormones (Fig. 
4A, lane 4 and bottom). At 20 min of hormone treatment, 
32p-labelling of GR was lower in the presence of both hor- 
mones as compared to that in the presence of dexamethasone 
alone (Fig. 4B, lanes 6 and 7), consistent with the lower levels 
of nuclear-bound receptor (Fig. 4A, lanes 6, 7 and bottom: 
and Fig. 4B, bottom). We cannot explain the decrease in 
nuclear-bound receptor levels when both hormones are pres- 
ent. However, that could be due to rapid GR relocalization 
process. Thus, the nuclear-bound GR after 10 min of hor- 
mone action, is hyperphosphorylated in the presence of insu- 
lin. On the contrary, at 20 min of hormone treatment, GR 
levels are kept low in the presence of both hormones com- 
pared to the levels in the presence of dexamethasone alone but 
the state of GR phosphorylation is not altered. 
4. Discussion 
In this report we present evidence demonstrating that the 
functional consequence of the combinatorial action of cou- 
pling insulin and glucocorticoid signalling on an single copy 
of GRE confers synergistic transcriptional transactivation. I  
agreement with Pan et al. [30], we show here that a single 
GRE is a target of both hormones, thus excluding the con- 
tribution of other DNA binding transcription factors in 
MMTV-LTR activation by glucocorticoids and insulin [31 
33]. Moreover, we show that modulation of glucocorticoid 
action by insulin requires activated GR since the glucocorti- 
coid antagonist RU40306 inhibited the effect. It is postulated 
that cellular kinases can modulate the function of the GR by 
enhancing either its DNA binding ability [34] or its transacti- 
vation potential [35-37]. Since insulin activates intracellular 
signalling which stimulates protein kinases, we examined in 
more detail its involvement in modulating the GR functional 
properties. Using cells treated with one or both hormones, we 
were not able to detect any significant insulin dependent al- 
terations on GR binding to its cognate ligand or to the GRE. 
Moreover, band shift assays clearly demonstrated that neither 
the amount nor the mobility of the GR-GRE complex was 
changed, arguing against he existence of an insulin depended, 
GR-targeted factor, which stabilizes the GR-GRE interaction. 
To confirm the above results we studied the effect of GR 
deletion mutants in response to both hormones.As it is shown 
(Fig. 2), insulin-mediated increase of transactivation by GR 
requires neither the C'- nor the N'-terminal portion of the GR 
protein. It is generally accepted that alterations in nuclear- 
bound GR levels determine the degree of glucocorticoid-de- 
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pendent ranscription. In this context we examined insulin- 
mediated changes in glucocorticoid inducibility and nuclear- 
bound GR levels. Using a monoclonal antibody with high 
specificity to the rat GR [23], we could detect high levels of 
nuclear-bound GR after 10 rain of steroid treatment, in agree- 
ment with previous tudies [38]. However, the combination of 
both hormones produced a dramatic decrease in nuclear- 
bound GR levels after 10 rain of treatment. This apparently 
contrasts the insulin-induced increase of transactivation by 
GR. Taking into account that the GR is a phosphoprotein 
and that, as with several other activators [39], its putative 
phosphorylation may affect its transcriptional activity, we 
tested the possibility of insulin induced modifications in the 
GR phosphorylation state. Indeed, the presence of insulin 
dramatically increased the dexamethasone-induced phosphor- 
ylation of nuclear-bound GR, a fact which was invariably 
observed after 10 rain of hormone treatment. Our results 
strongly suggest hat enhancement of GR transactivation po- 
tency by insulin correlates with hyperphosphorylation of nu- 
clear-bound GR. Since the above phenomenon requires the 
presence of the GR cognate ligand we assume that a sequence 
of events is taking place. Namely, either insulin phosphory- 
lates GR at critical sites different from those affected by its 
cognate ligand or a hierarchical phosphorylation occurs in 
which hyperphosphorylation by insulin is the consequence 
of the glucocorticoid-induced phosphorylation. Another hy- 
pothesis to explain our results is that insulin activates its re- 
ceptor tyrosine kinase which in turn influences nuclear-tar- 
geted signalling responsible for the potentiation of 
transactivation by GR. Our results represent also a molecular 
mechanism by which two different signalling pathways can 
cross-talk in modulating ene expression. 
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